VM Oncology, a clinical-stage precision oncology company, is currently developing a first-of-its-kind, oral, allosteric (non-ATP site) and irreversible, and selective TrkA inhibitor, VMD-928, for tumor-agnostic therapy. VMD-928 is purpose-designed to overcome treatment-resistant ATP-site mutations caused by existing ATP-competitive inhibitors, and to treat cancer beyond fusion-driven tumors with unique built-in-biomarkers. Ongoing P1 study show VMD-928 is safe and well tolerated. Pharmacological and analgesic activities beyond fusion target coverage were observed. Orphan drug designation granted. Strong IP protection with freshly granted COM patents. Further, the anti-inflammatory and analgesic activities make VMD-928 the best partner of choice for the combination therapy with immune checkpoint inhibitors. The company is managed by the same team of VM Pharma whose clinical-stage asset of first-in-class, oral allosteric kinase inhibitors for chronic pain was acquired by Purdue Pharma.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):